We are a pioneering biotech with world-class expertise to combat anti-microbial resistance and make a profound difference to humanity.

Click through to any subsequent page to learn more:

About Micreos

Imagine a world where antibiotics no longer work. Unfortunately, this is already a reality for many patients as the rise of antimicrobial resistance is rendering antibiotics increasingly ineffective.

Micreos is a clinical-stage pharmaceutical biotech developing medicinal solutions that selectively kill only harmful bacteria while preserving the rest of the health-enhancing microbiome.

Our vision is to positively impact patient care while helping global health care systems to address impending anti-microbial resistance (AMR) concerns.

Our unique capability in modular engineering to optimize enzyme therapeutics means that we have already developed four endolysin-based investigational antimicrobials.

These antimicrobials are focused on the detrimental impact of Staphylococcus aureus (S. aureus) in oncology, dermatology, wound-care and bloodstream infections.

Our team is forging ahead, partnering across medicine, to realize the shared goal of better solutions to combat harmful bacteria in an era of antimicrobial resistance.

Welcome to Micreos.
Beyond resistance

Our approach

Our approach is rooted in an ambition to make a profound difference to humanity.

To do this, we are focused on the challenges facing modern medicine in the 21st century by selecting and engineering biological alternatives to current antibiotics, which are increasingly powerless to combat bacterial infections.

Currently our investigational treatments are being evaluated in four therapeutic areas where burgeoning antibiotic resistance, or concerns about it, leave patients with increasingly limited options:

  • Cutaneous T-cell lymphoma, a rare skin cancer where S. aureus colonization can accelerate disease progression.
  • Atopic dermatitis, a skin condition causing misery to millions, where S. aureus is associated with more frequent flares and disease progression.
  • Diabetic foot ulcer, a common complication of uncontrolled diabetes where roughly 50% of all wounds ends up getting infected by harmful bacteria.
  • Bacterial bloodstream infections, a medical emergency with mortality rates of 10-30% and where antibiotic resistance is on the rise.

Leadership team

The past, present and future of Micreos is the result of the talent and integrity of outstanding individuals at every level of the business. Here we showcase the senior team at Micreos, to give an insight into our highly driven team:

CEO, Matt Regan

29+ years of Pharma, Med-Tech & Diagnostic experience spanning the entire value-chain from drug discovery & development to manufacturing to commercial leadership in large, global healthcare organizations.

CSO, Mathias Schmelcher

World-renowned endolysin researcher and ETH University lecturer.

CDO, Carsten Edwards

30+ years of diverse experience in drug development, pharmaceutical value, access & pricing, as well as a renowned expert on health economic outcomes research.

CMO, Johan Frieling

MD with deep expertise in microbiome and biotech development.

CBO, Trine Ahlgreen

20+ years of pharma experience in global, regional and affiliate roles in a large pharmaceutical company.

CHRO, Bonnie Veerhook

Successfully built the Arena Pharma international HR function and managed the subsequent transition to Pfizer post-acquisition.

Our vision

We are a pioneering biotech with world-class expertise to combat anti-microbial resistance and make a profound difference to humanity.

Micreos pipeline

From discovery to launch: transforming the treatment of chronic and acute bacterial infections.

*Data from a phase I/II study in patients with AD (n=39; 13 placebo and 26 active treatment) shows that XZ.700 in concentrations up to 100 ug/g is safe and well tolerated for twice daily administration for up to 14 days to patients with mild to moderate AD.

We welcome collaboration with partners who share our ambition to address the impact of bacterial infection on chronic and acute illness.
Please contact Natalie Samuel:

Get in touch